Skip to main content

Mark Lewis

Mark Lewis has become CEO of Swift Biosciences, replacing Tim Harkins. Most recently, he held senior vice president roles in product development, general management, and customer support at Illumina. Previously, Lewis held R&D, commercial, and general management roles at various other companies, including BD Biosciences, Molecular Dynamics, Nycomed-Amersham, and Beckman Instruments. He holds a BA in biology from the University of California, San Diego.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.